
| |  | |  | |
| Chromate-Induced Epimutations in Mammalian Cells Catherine B. Klein, Lin Su,* Darlene Bowser, and Joanna
Leszczynska New York University School of Medicine, Nelson Institute of Environmental
Medicine, New York, New York, USA
Abstract Epigenetic gene silencing by aberrant DNA methylation of gene promoter regions is a nonmutagenic but heritable epigenetic mechanism that may mistakenly cause the silencing of important cancer-related tumor suppressor genes. Using a transgenic, V79-derived, mammalian cell line (G12) that contains a bacterial gpt reporter gene in its DNA, we can study carcinogen-induced gene inactivation by mutagenic as well as epigenetic DNA methylation mechanisms. Whereas numerous carcinogens have previously been shown to be mutagenic in these cells, a few carcinogens, including nickel, diethylstilbestrol, and X-rays, are also capable of silencing the G12 cell gpt transgene by aberrant DNA methylation. Here we report for the first time that carcinogenic potassium chromate salts can also induce aberrant DNA methylation in this system. In contrast insoluble barium chromate produced significant level of mutations in these cells but did not cause DNA methylation changes associated with transgene expression. Key words: chromate, DNA methylation, gpt transgene, V79 Chinese hamster cells. Environ Health Perspect 110(suppl 5) :739-743 (2002) . http://ehpnet1.niehs.nih.gov/docs/2002/suppl-5/739-743klein/abstract.html |
|
|
 |
This article is part of the monograph Molecular Mechanisms of Metal Toxicity
and Carcinogenicity.
Address correspondence to C.B. Klein, New York University School of Medicine,
Nelson Institute of Environmental Medicine, 550 First Ave., New York, NY 10016
USA. Telephone: (845) 731-3510. Fax: (845) 351-5280. E-mail: kleinc@env.med.nyu.edu
*Present address: Dept. of Biochemistry and Molecular Biology,
Faculty of Medicine, University of Calgary, Calgary, Alberta, Canada.
The authors gratefully acknowledge the assistance of S. Lasano, M. Solow,
and A. King in collecting the barium chromate mutants and in performing the
polymerase chain reaction experiments reported herein. We thank E. Snow for
helpful discussions of our initial findings. This research was supported in
part by National Institute of Environmental Health Sciences (NIEHS) grant
ES09845 to C.B.K. and by New York University (NYU) Kaplan Cancer Center grant
CA16087, and was facilitated by resources and services provided by the NYU/NIEHS
Center (ES00260) including the Molecular Biology and the Laboratory Supplies
and Services Facility Cores.
Received 5 March 2002; accepted 21 May 2002.
Chromium (Cr) is a well-documented animal and human carcinogen (1).
The biological and genotoxic effects of Cr exposure vary, depending on intracellular
Cr chemistry in the cell type of interest. Due to its rapid uptake by normal
cellular anion transport mechanisms, Cr(VI) has been considered the primary
carcinogenic form. However, reduced states of Cr are likely to participate in
cellular redox interactions contributing to oxidative stress, which can have
genotoxic outcomes. Within cells, Cr(VI) is reduced to lower valencies (V to
II) by a variety of reductants, including cellular thiols (e.g., glutathione
[GSH]), NADPH, and ascorbate, to form reactive oxygen species (ROS), thiyl,
and carbon-based radicals [reviewed in Kaltreider et al. (2) and Liu
et al. (3)]. The complex intracellular reduction chemistry of Cr can
produce DNA damage, Cr-mediated DNA adducts, DNA-DNA and DNA-protein cross-links,
and mutations [reviewed in DeFlora et al. (4) and Klein (5)].
Cr can also inhibit DNA replication and repair [reviewed in Snow (6)],
alter gene expression (7,8), activate stress-response pathways (2,9),
trigger apoptosis (10,11), and damage chromosomes [reviewed in DeFlora
et al. (4) and Klein (5)].
Using soluble chromate salts and insoluble barium chromate (BaCrO4;
Aldrich Chemicals, Milwaukee, WI, USA), we studied the genotoxic effects of
Cr in Chinese hamster G12 lung cells. These transgenic cells allow the characterization
of a mixed spectrum of genotoxic outcomes that may include genetic mutations,
transgene deletions, and epigenetic gene silencing caused by aberrant DNA hypermethylation.
In previous studies we have shown that the gpt transgene in G12 cells
can be mutated or otherwise inactivated by numerous mutagens and carcinogens,
including ultraviolet (UV) radiation, N-methyl-N´-nitro-N-nitrosoguanidine
(MNNG), X-rays, bleomycin, nickel, chromate, 17ß-estradiol, diethylstilbestrol
(DES), nitric oxide, and oxidant generators such as glucose oxidase. The mutation
spectrum induced by each of these agents differs significantly. For example,
MNNG and UV induce primarily base-substitution mutations (12,13), X-rays
and bleomycin induce frequent deletions (13), and carcinogenic nickel
induces DNA methylation epimutations (variants) almost exclusively (14).
The nickel effect involves nickel, histone, and chromatin interactions in the
DNA that promote condensation of heterochromatin in the vicinity of the transgene
(14,15).
In support of the concept that chemical and physical carcinogens may exert
their effects by interacting with a variety of cellular processes, we found
that DES and X-rays can produce a mixed spectrum of DNA mutations (e.g., deletions
and point mutations) and epimutations (hypermethylation) in the transgenic gpt
target of G12 cells (16). These observations prompted us to reexamine
the mutagenic spectrum induced by Cr in these cells to investigate whether DNA
hypermethylation could be detected in any of the nondeletion mutants. Molecular
analysis of a panel of chromate-induced mutants shows a mixture of deletions
and epimutations (or variants), with the deletion versus methylation frequencies
being similar to those induced by X-rays in these cells. In contrast, studies
with insoluble BaCrO4 have provided substantial evidence of gpt
deletions but no evidence of altered DNA methylation.
Materials and Methods
Cell Culture and Generation of gpt- Mutants
or Methylation Variants
The G12 gpt+ cells were grown in F12 medium (Invitrogen
Corp., Life Technologies, Inc./Gibco, Grand Island, NY, USA) supplemented with
5% fetal bovine serum (Omega Scientific, Tarzana, CA, USA) and 1% penicillin/streptomycin
(Invitrogen Corp., Life Technologies, Inc., Grand Island, NY, USA) at 37°C
in a humid atmosphere (5% CO2). Standard mutagenesis protocols for
the selection of the 6-thioguanine resistance (6TGR) gpt-
phenotype in G12 cells were followed as previously described (12,13,17).
In brief, cells were treated with soluble potassium chromate (K2CrO4;
Fisher, Pittsburgh, PA, USA) (5-50 µM) or insoluble BaCrO4
(0.05-0.25 µg/cm2), then allowed a 7-day expression period
in nonselective F12 medium prior to being plated for mutant selection in 10
µg/mL 6TGF12 medium [reviewed in Klein et al. (18)]. K2CrO4
treatments were for 2 hr (12,19,20) at 37°C in magnesium-supplemented
salts glucose medium (SGM; 50 mM HEPES buffer, 100 mM NaCl, 5 mM KCl, 2 mM CaCl2,
0.8 mM MgSO4, pH 7.2). Insoluble BaCrO4 treatments were
for 24 hr at 37°C in complete F12 medium rather than in SGM because the
G12 cells do not tolerate salt buffers for lengthy exposures, even when supplemented
with glucose, as we have previously reported (19). In contrast to the
K2CrO4 exposures (2 hr), the BaCrO4 exposures
were for 24 hr to allow either dissolution of Cr from the particles, if it occurs,
or to allow time for phagocytic uptake of the particles by the G12 cells similar
to that which occurs for insoluble nickel compounds (20, 21). Also similar
to the way in which we have previously studied insoluble nickel compounds (20,21),
the insoluble BaCrO4 doses are expressed as micrograms BaCrO4
per square centimeter surface area of the tissue culture dish, as these insoluble
particles (sized at 0.4-0.6 µM) will tend to settle out during the
24-hr exposure time. The dose range of K2CrO4 or BaCrO4
chosen for mutagenesis studies corresponds to those doses that fell within the
comprehensive 20-100% survival curve generated for each Cr compound.
For the collection of independent chromate-induced 6TGR clones,
individually treated minicultures of 104 G12 cells were treated with
various doses of K2CrO4 in 35-mm wells of 6-well dishes,
and the cells were handled as independent cultures throughout the entire 6TG
selection process. Only one mutant per treated population was isolated and frozen
for further analysis. The doses of each compound chosen for subsequent mutant
isolation were either the maximal mutagenic dose (BaCrO4) or a variety
of doses (K2CrO4). All reagents and biochemicals were
acquired from Sigma Biochemical Company (St. Louis, MO, USA), unless otherwise
specified.
Analysis of Deletion Mutations and DNA Methylation in G12 Cells
A panel of independent 6TGR mutants/
epimutants derived from the various chromate treatments was evaluated for deletion
or methylation of the transgene. High molecular weight DNA was extracted from
0.5 to 1
107 mutant G12 cells following standard nonphenol extraction protocols
and was screened by polymerase chain reaction (PCR) to detect total or partial
deletions of the gpt target gene as per Klein et al. (13). The
single PCR primer set used generates a single 561-bp PCR amplification product
from G12 cells and their nondeleted mutants.
The methylation status of the gpt transgene and its proximal 5´
promoter region was examined on Southern blots for all nondeletion mutants as
previously described (14). In brief, Hpa II (CCGG) or Hae II(GCGC) digested
Eco RV fragments of G12 DNA containing the gpt transgene and proximal
promoter regions were separated in agarose, then transferred to Nytran Supercharge
(Schleicher and Schuell, Keene, NH, USA) membranes by capillary transfer or
vacuum blotting and UV linked (Stratalinker, Stratagene, La Jolla, CA, USA)
to the membrane. Blots were prehybridized for 6 hr at 68°C (in 1% nonfat
dry milk, 0.1 mM EDTA, 6% NaH2PO4, 7% sodium dodecyl sulfate,
pH 7.0 ), followed by overnight probe hybridization in a fresh solution of the
same buffer with 10% dextran sulfate. Probes derived from the pSV2gpt plasmid
that was originally transfected into V79 cells to create the G12 cells were
labeled to a high specific activity (>109 counts per min/µg
DNA) by random priming or PCR incorporation of 32P. The hybridized
membranes were imaged and analyzed using a Storm 860 PhosphoImager (NYU/NIEHS
Center, Molecular Biology Facility Core).
Reversion Studies in G12 Cells
To confirm the methylation silencing of the gpt transgene induced by
chromate, 5-azacytidine-induced reversion to HAT (100 µM hypoxanthine,
1 µM aminopterin, 100 µM thymidine) resistance was examined. In brief,
a representative sampling of G12 epimutants that exhibited evidence of DNA methylation
on Southern blots were treated with 5-azacytidine (5 µM) for 48 hr followed
by a 24-hr recovery period prior to selection of revertants in F12HAT medium
(14,21). HAT-resistant clones were stained and counted after 2-3
weeks in selection.
Results
Figure 1 shows that K2CrO4 (5-50 µM) was mutagenic in
G12 cells over a completely toxic dose range, with maximal mutation induction
(3
background levels) peaking at 40 µM (about 40% survival), as we have previously
reported (19,20). Similarly, insoluble BaCrO4 was mutagenic
(Figure 2) in G12 cells, with a maximal mutation peak (3.5
background) observed at 0.15 µg/cm2 (75% survival). Notable in both
of these figures (Figures 1B, 2B) is the peak in mutagenesis levels followed
by a decline, and the broadness of the error bars. These features are characteristic
of the mutagenesis profiles generated by us and others in various mammalian
cells by Cr (22,23), by other metals such as nickel oxides (12,20),
and by oxidants including nitric oxide, hydrogen peroxide, and glucose oxidase
(24). Interestingly, chromate-induced mutagenesis at the Na+K+-ATPase
(ouabain resistance) gene was not recoverable in either G12 or their parent
V79 cells (data not shown). These results support our findings, described below,
showing that chromate primarily induced a mixture of deletion mutants and methylation
variants that would not be recoverable at the Na+K+-ATPase
gene due to the tight limitations of the ouabain resistance selection mechanisms
(12).

Figure 1. Survival and mutagenesis
of G12 cells treated with K2CrO4. K2CrO4 exposures were for 2 hr at 37°C
in magnesium-supplemented SGM. Clonal cell survival (% control) is depicted
in (A), and the corresponding mutagenesis is shown in (B). The data points
represent the mean of 3–5 independent experiments, with error bars denoting
standard error of the means. |

Figure 2. Survival and mutagenesis
of G12 cells treated with BaCrO4. Insoluble BaCrO4 treatments were for 24
hr at 37°C in complete F12 medium. Clonal cell survival (% control) is depicted
in (A), and the corresponding mutagenesis is shown in (B). The data points
represent the means of 2–3 independent experiments, with standard error
of the means shown by error bars for doses where at least three data points
were available. |
K2CrO4
generated gpt transgene deletions in 5 of the 12 6TGR G12
mutants depicted in the PCR panel in Figure 3. These mutants were induced by
an increasing range of K2CrO4 doses as follows: 12Cr1L
and 1S by 5 µM; 12Cr2L and 2S by 10 µM; 12Cr3L and 3S by 20 µM; 12Cr4L and 4S
by 30 µM; 12Cr5L and 5S by 40 µM; and 12Cr6L and 6S by 50 µM. Among 15 K2CrO4-generated
G12 mutants we have examined to date, 53% exhibited complete deletion of the
gpt transgene. This frequency of chromate-induced deletions was in the
same range of transgene deletion frequencies previously described for approximately
equitoxic doses of X-rays (48%) and bleomycin (57%) in these same cells (13).
In comparison, about 20% of spontaneous G12 mutants exhibit transgene deletions
(13). Additionally, the chromate-induced deletion frequency in G12 cells
was identical to that observed for deletions of exons 3 and 6 of the hprt
gene (14/27 = 52%) in the parental V79 cells (Table 1). Figure 4 shows PCR-deletion
screening of a sampling of BaCrO4-induced mutations in G12 cells.
In total, we have identified 33% (8/24) deletion mutants from G12 cells exposed
to insoluble BaCrO4. This deletion frequency is slightly less than
that noted above for K2CrO4 mutants. Until now, very little
was known about the type of mutations that would be induced by insoluble BaCrO4
(4).

Figure 3. PCR amplification of
the gpt sequence in G12 cells and K2CrO4-induced G12 mutants. MWM, molecular
weight marker. High molecular weight DNA was extracted from mutant G12 cells
and was screened by PCR to detect total or partial deletions of the gpt
target genes as shown on agarose gels. The single PCR primer set used generates
a single 561-bp PCR amplification product from G12 cells and any nondeleted
mutants. K2CrO4 exposure doses (2 hr in SGM) were as follows: 12Cr1L and
1S = 5 µM; 12Cr2L and 2S = 10 µM; 12Cr3L and 3S = 20 µM; 12Cr4L and 4S =
30 µM; 12Cr5L and 5S = 40 µM; and 12Cr6L and 6S = 50 µM. |

Figure 5. Methylation of the gpt
gene in K2CrO4-induced G12 mutants and variants. Lane 1 = EcoRV-digested
control G12 DNA. Lanes 2 and 3 are unmethylated control G12 DNA. All genomic
DNA was first digested with EcoRV, then DNA in lanes labeled A were subsequently
digested with Hpa II, and those labeled B were digested with Hae II. Cr3S
to Cr7L are K2CrO4 -induced 6TG-resistant G12 variants. All variants except
the Cr1L deletion mutant show methylation of the gpt gene, as observed by
the 1.7-kb band in HaeII digests (B) and 0.98-kb band in HpaII digests (A).
In Cr1L, the gpt gene was deleted, as previously shown by PCR. The mutants
denoted by shorthand in this figure as Cr3S, Cr1L, etc., are identical to
those labeled as 12Cr3S, 12Cr1L, etc. described elsewhere. |

Figure 6. Methylation blot of
BaCrO4-induced mutants of G12 cells. Lane 1 = EcoRV-digested control G12
DNA. Lanes 2 and 3 are unmethylated control G12 DNA. All lanes labeled A
are digested with Hpa II, and those labeled B are digested with Hae II,
after intial digestion with EcoRV. 12CrI1 to 12CrI5 are BaCrO4-induced,
6TG-resistant G12 variants. The gpt gene was deleted in 12CrI1 and 12CrI2,
as shown above by PCR. There is a complete lack of induced DNA methylation
in mutants 12CrI3, 12CrI4, and 12CrI5. |
DNA methylation analysis of the gpt transgene and 5´ promoter region
in several K2CrO4-induced mutants is shown in Figure 5.
Compared with the completely unmethylated status of control untreated G12 DNA
(lanes 2 and 3), there is evidence of partial methylation of the gpt transgene
in Cr variants Cr3S, Cr4S, Cr5S, Cr5L, Cr6L, and Cr7L, as detected by the presence
of a 0.98-kb band in the HpaII lanes (Figure 5A) and the 1.7-kb band in the
HaeII lanes (Figure 5B). In these studies, almost all nondeleted chromate-induced
variants exhibit partial methylation of the transgene. In comparison, only 10%
of spontaneous G12 mutants have their transgene silenced by DNA hypermethylation.
The Cr mutant Cr1L was previously shown to be deleted by PCR (Figure 3). In
contrast to this K2CrO4 data, insoluble BaCrO4
did not induce any DNA methylation changes in G12 cells, as shown in the representative
panel of mutants examined (Figure 6).
Similar to the partial DNA methylation pattern shown above (Figure 5) for
the Cr methylation variants and for some X-ray G12 variants (Figure 7, lanes
3 and 4), nickel-induced variants also exhibited some degree of incomplete or
partial methylation of the G12 transgene by nickel (14), as evidenced
by acquisition of 1.7-kb HaeII bands accompanied by incomplete loss of th e
unmethylated 1.2-kb bands. This could represent either incomplete methylation
or reversion loss of methylation in some cells. In the Cr studies it is possible
that the partial methylation we observe is due to the short exposure to chromate
(2 hr), and we are presently examining the DNA methylation status of G12 cells
exposed to chromate for longer exposures (24-48 hr) as well as chronic exposures
(2-6 weeks) to low chromate doses. However, others have reported that 1- to
2-hr exposures of mammalian cells to soluble chromate is sufficient to induce
a variety of transcription regulators, including AP1, nuclear factor kappa B,
and Sp1 (2,8).
 |
Figure 4. PCR amplification
of the gpt sequence in G12 cells and BaCrO4-induced
G12 mutants. High molecular weight DNA was screened by PCR to detect total
or partial deletions of the gpt target gene, as shown on agarose
gels. All BaCrO4 exposures were 0.15 µg/cm2 (24
hr) in complete F12.
|
A
measurable degree of spontaneous reversion, accompanied by demonstrable loss
of DNA methylation, occurs in nickel-induced methylation variant cell populations,
allowing the gpt transgene to regain functional expression in a substantial
proportion of the cells (14). However, the Cr-induced variant cells discussed
herein were continuously grown in 6TGR selection until the time of
DNA extraction, thus eliminating the possibility of any spontaneous reversion
at this point. Furthermore, epigenetic silencing of gpt in G12 cells
can be completely reversed by treatment of silenced cells with the methylation
inhibitor 5-azacytidine (14) or with a combination of 5-azacytidine and
the histone deacetylase inhibitor trichostatin A (15), as demonstrated
for nickel-silenced cells. We show here (Table 2) that chromate-induced methylation
variants are also subject to 5-azacytidine-mediated reversion of transgene silencing,
as are methylation variants induced by X-rays and DES (data not shown). The
reversion frequencies shown in Table 2 are similar to those previously reported
for nickel-induced methylation variants (14). Whereas spontaneous reversion
of nickel-induced variants occurs at a frequency of about 10-4, we
have not yet investigated the spontaneous reversion of the chromate variants,
but we anticipate it will be similar.
 |
Figure 7. DNA Methylation
of gpt in X-ray-induced G12 epimutants-Hae II digests. Lane 1 = EcoRV-digested
control G12 DNA. Lane 2 is a nonmethylated, nonrevertible X-ray-induced
mutant (12X3-S10). Lanes 3 and 4 are partially methylated, 5-azacytidine-revertible
X-ray-induced G12 variants (12X3-S11 and 12X3-S12). |
Discussion
Based on our knowledge of the myriad Cr-induced mutagenic, clastogenic, and
carcinogenic effects (5), including evidence characterizing numerous
Cr-induced base substitution mutations (22,25), it was not surprising
that such a high frequency of gpt deletions was recovered in the G12
mutation experiments. Although it was possible that Cr-induced mutagenic base
substitutions could have occurred in the PCR primer sites to eliminate gpt
sequence amplification, the transgene deletions observed by PCR screening were
confirmed on Southern blots of genomic DNA. These deletions are not inconsistent
with the activity of reactive oxygen or other reactive radicals that may be
generated during GSH or other reductant-mediated intracellular reduction of
Cr(VI) to Cr(III). In support of this, Cr induced DNA strand breaks when reduced
by ascorbate or glutathione [reviewed in Klein (5)]. Furthermore, Cr(VI)/GSH-
or Cr(VI)/peroxide-induced oxidation-mediated deletions of the pZ189 vector
supF gene in CV-1 cells have been reported for 43% of the mutants recovered
and analyzed in the experiments of Dixon and collaborators (3,26).
Similar to K2CrO4, insoluble BaCrO4 also
yielded a generous proportion of G12 deletion mutants. Indeed, little is known
about the mutagenic spectrum that can be induced in mammalian cells by BaCrO4
(4). Compared with sodium, calcium, and lead chromates, which generate
reactive oxygen radicals in serum-supplemented culture medium, BaCrO4
was reported to be inactive in ROS generation under similar circumstances (27).
Also in contrast to soluble K2CrO4, BaCrO4
was much less active in inducing pulmonary inflammation in rat inhalation studies
(28). It will be interesting to identify the DNA sequence mutations within
the nondeleted transgene in the as yet uncharacterized BaCrO4 mutants.
Although Cr is mutagenic in a variety of bacterial and mammalian systems [reviewed
in DeFlora et al. (4) and Klein (5)], the mutagenic potential
of Cr(VI) exposures is ambiguous in the literature. Yang et al. (22)
analyzed the mutagenic specificity of base substitution mutations caused by
Cr(VI) in the hprt gene of Chinese hamster ovary cells, finding predominantly
AT TA
or AT CG
mutations. These results correlated with previous studies of chromate mutagenesis
in Salmonella strain TA102, which is sensitive to mutations in A/T-rich
sequences (29). In contrast, Chen and Thilly (25) described four
hotspots for Cr mutagenesis in the endogenous human hprt gene, specifically
observing mutations of CG AT
or TA, CG AT,
and AT TA.
Similarly, Liu et al. (3) thoroughly characterized the mutations induced
by potassium dichromate in the supF gene of pZ189 shuttle vectors in
cultured mammalian (CV-1 monkey) cells, finding a predominance of mutations
at GC base pairs (GC AT,
GC CG,
GC TA).
These results are in general agreement with Chen and Thilly (25). In
closely examining the sequence context of the reported mutations in the Liu
study (3), it becomes evident that many but not all of the chromate mutations
are located at guanines and cytosines in CpG DNA sites. Our ongoing examination
of the entire gpt sequence in nondeleted methylation variants will reveal
whether intragenic CpG sites within the transgene are similarly mutated by Cr
at guanine or cytosine bases. This would not be unexpected, as there is already
sufficient precedent for some other carcinogens to react at CpG sites within
relevant cancer genes. For example, studies of benzo[a]pyrene mutations
in p53 have defined predominant mutation hotspots at guanines in methylated
CpG sites within the coding exons of p53 (30-32). Although
the mutation of a CpG site can easily be envisioned to result in the aberrant
loss of normal DNA methylation, it is also possible that mutation of CpG sites
may lead to aberrant DNA hypermethylation, perhaps through as yet undefined
DNA repair-mediated processes or by perturbations of those normal processes.
Our observations of DNA methylation silencing and 5-azacytidine-mediated
reversion of transgene expression following chromate exposure were unexpected.
Previously we reported that carcinogenic nickel (14) and the synthetic
estrogen DES (16) could silence expression of the gpt transgene
in G12 cells. Subsequently, we added X-rays and now chromate to the growing
list of carcinogens that have the capacity to induce DNA methylation silencing
of susceptible target genes. These carcinogens, with the exception of nickel,
all induce a mixed spectrum comprising varying proportions of classic gene mutations,
transgene deletions, and altered transgene promoter methylation that result
in the inactivation, loss, or silencing of the G12 reporter transgene. All epigenetically
silenced variants examined to date can be reactivated by 5-azacytidine to reexpress
the transgene, regardless of the carcinogen (nickel, chromate, DES, X-rays)
that caused the aberrant promoter or transgene methylation. Some degree of spontaneous
reversion also occurs for most variants. In contrast to nickel-induced methylation,
which causes formation of tightly condensed heterochromatin, our preliminary
data suggest that the methylation induced by chromate, DES, and X-rays may be
transient, and perhaps weaker, as suggested by DNase resistance studies. Temporal
studies are underway to further characterize the persistence of the altered
DNA methylation state, as the methylation blots shown herein clearly demonstrate
partial transgene methylation, as discussed above.
The relevance of these findings can be applied to the human cancer scenario,
for which the loss of expression of a multitude of tumor suppressor and DNA
repair has now been shown to result from aberrant DNA methylation (33).
In human tumors, aberrant DNA hypermethylation of the CDKN2/p16/MTS1
gene, for example, has been described for about 33% of breast cancers, 60% of
prostate cancers, 23% of renal cancers, and 92% of colon cancers cell lines,
as well as in 31% of primary breast cancer tumors and 40% of primary colon cancers
(34). DNA repair genes including O6-methylguanine-DNA
methyltransferase and the mismatch repair genes hMLH1and hMSH6
(35,36) are also subject to aberrant transcription silencing in tumors.
Even the human telomerase gene is subject to epigenetic DNA methylation silencing,
which may have significant ramifications in the carcinogenic process (37).
Recent studies of DNA hypermethylation in certain cancers suggest that methylation
changes in gene expression may in fact be early events in the carcinogenic process
(35,38).
In conclusion, accumulating evidence from retrospective studies of archived
and fresh breast, ovarian, colon, and many other human tumors has provided substantial
evidence that a variety of tumor suppressor and other crucial DNA repair and
damage control genes can be inactivated by DNA methylation silencing. However,
it is unknown from these tumor studies whether these DNA methylation changes
occur early in tumorigenesis, possibly resulting from environmental exposures,
or if they are late effects perhaps related to establishment, selection, and
perpetuation of the tumorigenic phenotype (39). Our data support the
emerging concept that gene-specific environmental exposure-related changes
in DNA methylation may be early events in the tumorigenic process. |
|
 |
| [References Listed in PubMed] References and Notes
1. IARC. Chromium, nickel and welding. IARC Monogr Eval
Carcinog Risks Hum 45:49-508 (1990).
2. Kaltreider RC, Pesce CA, Ihnat MA, Lariviere JP, Hamilton
JW. Differential effects of arsenic (III) and chromium (VI) on nuclear transcription
factor binding. Mol Carcinog 25:219-229 (1999).
3. Liu S, Medvedovic M, Dixon K. Mutational specificity
in a shuttle vector replicating in chromium(VI)-treated mammalian cells. Environ
Mol Mutagen 33:313-319 (1999).
4. DeFlora S, Bagnasco M, Serra D, Zanacchi P. Genotoxicity
of chromium compounds. Mutat Res 238:99-172 (1990).
5. Klein CB. Carcinogenicity and genotoxicity of chromium.
In: Toxicology of Metals (Chang LW, ed). Boca Raton, FL:CRC Press, 1996;205-219.
6. Snow ET. Metal carcinogenesis: mechanistic implications.
Pharmacol Ther 53:31-65 (1992).
7. McCaffrey J, Wolf CM, Hamilton JW. Effects of the genotoxic
carcinogen chromium(VI) on basal and hormone-inducible phosphoenolpyruvate carboxykinase
gene expression in vivo: correlation with glucocorticoid- and developmentally-regulated
gene expression. Mol Carcinog 10:189-198 (1994).
8. Hamilton JW, Kaltreider RC, Bajenova OV, Ihnat MA,
McCaffrey J, Turpie BW, Rowell EE, Oh J, Nemeth MJ, Pesce CA, Lariviere. Molecular
basis for effects of carcinogenic heavy metals on inducible gene expression.
Environ Health Perspect 106:1005-1015 (1998).
9. Kim G, Yurkow EJ. Chromium induces a persistent activation
of mitogen-activated protein kinases by redox-sensitive mechanisms in H4 rat
hepatoma cells. Cancer Res 56:2045-2051 (1996).
10. Carlisle DL, Pritchard DL, Singh J, Patierno SR. Chromium
(VI) induces p53-dependent apoptosis in diploid human lung and mouse dermal
fibroblasts. Mol Carcinog 28:111-118 (2000).
11. Pritchard DE, Ceryak S, Ha I, Fornsaglio JL, Hartman
SK, O'Brien TJ, Pateirno SR. Mechanisms of apoptosis and determination of cell
fate in chromium(VI)-exposed populations of telomerase-immortalized human fibroblasts.
Cell Growth Diff 12:487-496 (2001).
12. Klein CB, Su LX, Rossman, TG, Snow ET. Transgenic
gpt+ V79 cell lines differ in their mutagenic response to
clastogens. Mutat Res 304:217-228 (1994).
13. Klein CB, Su L, Singh JT, Snow ET. Characterization
of gpt- deletion mutations in transgenic Chinese hamster
cell lines. Environ Mol Mutagen 30:418-428 (1997).
14. Lee YW, Klein CB, Kargacin B, Salnikow K, Kitahara
J, Dowjat K, Zhitkovitch A, Christie NT, Costa M. Carcinogenic nickel silences
gene expression by chromatin condensation and DNA hypermethylation: a new model
for epigenetic carcinogens. Mol Cell Biol 15:2547-2557 (1995).
15. Sutherland JE, Peng W, Zhang Q-W, Costa M. The histone
deacetylase inhibitor trichostatin A reduced nickel-induced gene silencing inyeast
and mammalian cells. Mutat Res 479:225-233 (2001).
16. Su L, Klein CB. Molecular mechanisms of gene inactivation
by different mutagens [Abstract]. Proc Am Assoc Cancer Res 40:546 (1999).
17. Klein CB, Rossman, TG. Transgenic Chinese hamster
cell lines which exhibit variable levels of gpt mutagenesis. Environ
Mol Mutagen 16:1-12 (1990).
18. Klein C, Broday L, Costa M. In vitro genotoxicity
assays. Mammalian mutagenesis. In: Current Protocols in Toxicology, Vol 1 (Maines
MD, Costa LG, Reed DJ, Sassa S, Sipes I, eds). New York:John Wiley & Sons,
1999;3.3.1-3.3.7.
19. Klein CB, Su LX, Snow ET. Chromium mutagenesis in
transgenic gpt+ Chinese hamster cell lines [Abstract]. Environ
Mol Mutagen 19:29a (1992).
20. Klein CB, Su L, Kargacin B, Cosentino S, Snow ET,
Costa M. Metal mutagenesis in transgenic Chinese hamster cell lines. Environ
Health Perspect 102(suppl 4):63-67 (1994).
21. Kargacin B, Klein CB, Costa M. Mutagenic responses
of nickel oxides and nickel sulfides in Chinese hamster V79 cell lines at the
xanthine-guanine phosphoribosyl transferase locus. Mutat Res 300:63-72
(1993).
22. Yang JL, Hsieh YC, Wu CW, Lee TC. Mutational specificity
of chromium(VI) compounds at the hprt locus of Chinese hamster ovary-K1 cells.
Carcinogenesis 13:2053-2057 (1992).
23. Cheng L, Liu S, Dixon K. Analysis of repair and mutagenesis
of chromium-induced DNA damage in yeast, mammalian cells, and transgenic mice.
Environ Health Perspect 106(suppl 4):1027-1032 (1998).
24. Abu-Shakra A, Su L, Harris CE, Klein CB. Unpublished
data.
25. Chen J, Thilly WG. Mutational spectrum of chromium
(VI) in human cells. Mutat Res 323:21-27 (1994).
26. Liu S, Dixon K. Induction of mutagenic DNA damage
by chromium (VI) and glutathione. Environ Mol Mutagen 28:71-79 (1996).
27. Lefebvre Y, Pezerat H. Reactive oxygen species generated
from chromate pigments and ascorbate. Environ Mol Mutagen 104(suppl 3):243-245
(1994).
28. Cohen MD, Zelikoff, JT, Chen L-C, Schlesinger, RB.
Immunotoxic effects of inhaled chromium: role of particle solubility and co-exposure
to ozone. Toxicol Appl Pharmacol 152:30-40 (1998).
29. Bennicelli C, Camoirano A, Petruzzelli S, Zanacchi
P, DeFlora S. High sensitivity of Salmonella TA102 in detecting hexavalent
chromium mutagenicity and its reversal by liver and lung preparations. Mutat
Res 122:1-5 (1983).
30. Denissenko MF, Pao A, Tang M, Pfeifer GP. Preferential
formation of benzo[a]pyrene adducts at lung cancer mutational hotspots
in P53. Science 274:430-432 (1996).
31. Chen JX, Zheng Y, West M, Tang MS. Carcinogens preferentially
bind at methylated CpG in the p53 mutational hot spots. Cancer Res 58:2070-2075
(1998).
32. Pfeifer GP. p53 mutational spectra and the role of
methylated CpG sequences. Mutat Res 450:155-166 (2000).
33. Robertson KD, Jones PA. DNA methylation: past, present
and future directions. Carcinogenesis 21:461-467 (2000).
34. Herman JG, Merlo A, Mao L, Lapidus RG, Issa JP, Davidson
NE, Sidransky D, Baylin SB. Inactivation of the CDKN2/p16/MST1 gene is
frequently associated with aberrant DNA methylation in all common human cancers.
Cancer Res 55:4525-4530 (1995).
35. Esteller M, Catasus L, Matias-Guiu X, Mutter GL, Prat
J, Baylin SB, Herman JG. hMLH1 promoter hypermethylation is an early
event in human endometrial carcinogenesis. Am J Pathol 155:1767-1772 (1999).
36. Bearzatto A, Szadkowski M, Macpherson P, Jiricny J,
Karran P. Epigenetic regulation of the MGMT and hMSH6 DNA repair
genes in cells resistant to methylating agents. Cancer Res 60:3262-3270
(2000).
37. Horikawa I, Cable PL, Afshari C, Barrett JC. Cloning
and characterization of the promoter region of human telomerase reverse transcriptase
gene. Cancer Res 59:826-830 (1999).
38. Di Croce L, Raker VA, Corsaro M, Fazi F, Fanelli M,
Faretta M, Fuks F, Lo Coco F, Kouzarides T, Nervi C, et al. Methyltransferase
recruitment and DNA hypermethylation of target promotors by an oncogenic transcription
factor. Science 295:1079-1082 (2002).
39. Costa M, Klein CB. Nickel carcinogenesis, mutation,
epigenetics or selection [Editorial]. Environ Health Perspect 107:A438-A439
(1999).
Last Updated: October 9, 2002 |
|
 |
|
| |